Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04739800
Title Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

ovarian cancer

fallopian tube cancer

peritoneum cancer


Paclitaxel + Pegylated liposomal doxorubicin + Topotecan

Cediranib + Durvalumab

Cediranib + Olaparib

Cediranib + Durvalumab + Olaparib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.